No longer limited by yesterday’s knowledge and technology, our patient-focused approach, coupled with compelling science, has attracted some of the boldest and most accomplished leaders in the medical and pharmaceutical industry — including several C-Suite Executives from one of the first-ever gene therapy companies to successfully bring a treatment to market.

With a team of established experts, we are perfectly positioned to advance our therapy to the patients who need it, quickly and safely.

BOARD OF DIRECTORS & MANAGEMENT

Hans Sollinger

Hans Sollinger, MD, PhD, Dr hc Founder & CSO, Board member
A world leader in diabetes care for decades, who has earned numerous awards for contributions that have revolutionized the field. More details »

Eric Spyra President & CEO, Board member
Experienced investor with a strong development background and unique connection to Dr. Sollinger’s work. More info »

Adam J. Bock, MBA, PhD CFO
Experienced life science startup executive. Co-founder / Founding CEO of 4 life science ventures. More info »

José Rivera Board member
José has 25+ years of experience as a biopharmaceutical attorney and executive in both biopharmaceutical start-ups and large cap healthcare companies. More info »

Thomas J. Dee, MBA Board member
Entrepreneurial biotech CFO who helped break one of the first FDA-approved gene therapies onto the market. More info »

Elizabeth Aden, PhD Board member
30+ years including multinational executive leadership in biotechnology and pharmaceutical product planning, strategic marketing and business development. More info »

SCIENTIFIC ADVISORY BOARD

Brian Kaspar, PhD Scientific Advisory Board member
Pioneering founder & previous Chief Scientific Officer of the company that developed one of the first companies to commercialize a gene therapy treatment. More info »

Peter Thule

Peter Thule, MD Scientific Advisory Board member
World-renowned endocrinologist, and the only other researcher with in-depth experience and success researching AAV gene alteration of hepatocytes. More info »

Jim L’Italien, PhD Scientific Advisory Board member
30+ years of senior-level VP leadership in regulatory affairs, and helped blaze the trail for one of the first-ever gene therapies to successfully earn FDA approval. More info »

David Pauza, PhD Scientific Advisory Board member
Globally recognized expert in human virology, viral diseases and viral vectors for gene therapy who holds 15 gene therapy patents, and has been funded continuously by the N.I.H. for nearly 30 years. More info »